Abstract
The article deals with the newest findings about pharmacological, systemic treatment of hepatocellular carcinoma (HCC) using sorafenib (Nexavar). It refers to the original registration study, which clearly proved the efficacy of sorafenib.
Results are presented from the 1st and 2nd interim analysis performed as a part of the world's largest global nonintervention observation prospective study called GIDEON, which presents evidence for why is sorafenib treatment of advanced HCC justified. Other studies focusing on the same preparation are mentioned as well.
International recommendations for HCC treatment are presented, which are compatible with the recommendations issued by the Czech Oncologic Society (a part of the Czech Medical Association of J.E.Purkyně).